VivaTech 2019: Thales Receives Global Innovator Award and Invites Visitors to Be Astronauts for a Day
7.5.2019 08:00:00 EEST | Business Wire | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005645/en/
"Thales Alenia Space". Copyright: Thales
Global recognition for research and innovation
The Derwent Top 100 Global Innovators ranking recognises the volume, success and influence of the patents filed by technology companies. Thales has appeared six times in this prestigious ranking, reflecting the company’s commitment to innovating, bringing inventions to market and protecting its ideas.
This distinction comes at a turning point in Thales’s history. With the completion of the acquisition of Gemalto on 2 April, the Group now employs 28,000 engineers, devotes €1 billion a year to self-funded R&D and maintains a portfolio of 20,500 patents, including 400 filed in 2018. At the show, Thales will also sign the LGBT+ Charter championed by Autre Cercle, thus highlighting the group’s strategy of promoting diversity and inclusion across its talent pool, as a way to free creative potential and foster innovation.
Thales at VivaTech: AI for every decisive moment
Thales will be showcasing its latest innovations alongside some 30 start-ups from six countries specialising in artificial intelligence, connectivity, drone technology, cybersecurity and robotics.
A series of demonstrations will show how advanced technology helps real-life users to understand the most complex situations:
- Columbus invites visitors to feel what it’s like to be an astronaut on-board the International Space Station’s science laboratory.
- The autonomous train demonstrator lets visitors drive a New York City subway train and see how they match up to the capabilities of artificial intelligence.
- Piume allows users to experience what it’s like to be an explorer or a researcher working in harsh environments.
- Geonav uses the Galileo satellite constellation to prevent risks faced by high-level athletes, without the dropped signals that often occur inside sports stadiums.
- Smart New World combines the power of holographic displays with IoT (Internet of Things) technology.
- The 3D interactive hologram table developed with the Australian start up Euclideon models anything you can imagine: cities, objects, design techniques and much more.
Thales experts will also be taking part in around 40 panel sessions to discuss how artificial intelligence that is trustable, explainable and certifiable can be used to invent or reinvent the cities of the future, develop autonomous trains and future medical imaging solutions, protect the environment and take space exploration to the next frontier. The schedule for the demonstrations and panel sessions can be found on the Thales event website.
Thales Decisive Journeys at VivaTech
- DecisiveJourney#1: From space observation to personal data protection: find out how trusted AI is a decisive technology for Thales
- DecisiveJourney#2: Thales technologies applied to environmental protection
- DecisiveJourney#3: Artificial nano-neurons and medical imaging: Thales innovations reshaping the future of medicine
- DecisiveJourney#4: How to develop responsible AI
- DecisiveJourney#5: How digital is changing our companies and work methods
About Thales
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018
PLEASE VISIT
Thales
Group
Twitter: @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005645/en/
Contact information
Thales, Media Relations
Alice Pruvot +33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom